QTRX Quanterix Corp
Laboratory Analytical Instruments · Nasdaq · SEC CIK 1503274 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY13.8%
TTM net income YoY-16.2%
TTM EPS YoY0.0%
Revenue 3-yr CAGR8.3%
Net income 3-yr CAGR—
Margins
Gross margin41.7%
Operating margin-93.2%
Net margin-75.0%
FCF margin-37.8%
EBITDA margin-76.7%
Returns
ROE-41.7%
ROA-29.9%
ROIC (approx.)-47.4%
Asset turnover0.40x
Leverage & solvency
Liabilities / assets27.0%
Debt / equity0.00x
Current ratio3.09x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.50x
Accruals ratio-14.9%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $138.90M | $137.42M | $122.37M | $105.52M | $110.56M |
| Cost of revenue | $73.94M | $54.32M | $48.14M | $60.16M | $45.78M |
| Gross profit | $64.96M | $83.10M | $74.22M | $45.36M | $64.77M |
| R&D expense | $35.92M | $31.08M | $26.06M | $26.81M | $28.38M |
| SG&A expense | $138.01M | $101.62M | $89.11M | $91.85M | $92.91M |
| Operating income | -$125.54M | -$52.62M | -$45.99M | -$104.26M | -$56.52M |
| Pretax income | -$112.27M | -$38.10M | -$27.64M | -$99.41M | -$55.58M |
| Income tax | -$5.12M | $434,000 | $719,000 | $164,000 | -$36,000 |
| Net income | -$107.15M | -$38.53M | -$28.35M | -$99.57M | -$55.55M |
| EBITDA | -$109.70M | -$46.15M | -$39.72M | -$98.86M | -$51.64M |
| EPS (basic) | -2.51 | -1.00 | -0.75 | -2.69 | -1.54 |
| EPS (diluted) | -2.51 | -1.00 | -0.75 | -2.69 | -1.54 |
| Weighted avg. shares (diluted) | 42.64M | 38.37M | 37.59M | 36.99M | 36.00M |
| Banking | |||||
| Net interest income | $8.57M | $14.65M | $15.84M | $5.13M | -$403,000 |
| Provision for credit losses | $1.47M | $712,000 | $729,000 | $752,000 | $213,000 |
| Balance sheet | |||||
| Cash & equivalents | $29.84M | $59.32M | $177.03M | $341.34M | $399.27M |
| Short-term investments | $88.39M | $232.41M | $6.89M | $0 | — |
| Receivables | $29.97M | $32.14M | $25.41M | $19.02M | $23.79M |
| Inventory | $54.76M | $32.77M | $26.12M | $16.96M | $22.19M |
| Current assets | $212.26M | $363.59M | $382.10M | $381.52M | $448.95M |
| PP&E, net | $23.67M | $17.15M | $17.93M | $19.81M | $17.96M |
| Goodwill | $26.38M | $0 | $0 | $0 | $9.63M |
| Intangibles | $131.79M | $4.03M | $6.03M | $7.52M | $10.53M |
| Total assets | $418.77M | $406.53M | $428.57M | $433.58M | $501.53M |
| Current liabilities | $74.76M | $42.01M | $38.98M | $31.35M | $36.98M |
| Total liabilities | $123.04M | $76.50M | $78.61M | $75.65M | $60.58M |
| Shareholders' equity | $295.73M | $330.04M | $349.96M | $357.93M | $442.79M |
| Shares outstanding | 46.74M | 38.57M | 38.01M | 37.28M | 36.77M |
| Cash flow statement | |||||
| Operating cash flow | -$77.24M | -$35.16M | -$18.85M | -$48.61M | -$47.62M |
| Capital expenditure | $2.61M | $3.37M | $3.84M | $11.61M | $13.68M |
| Free cash flow | -$79.85M | -$38.53M | -$22.69M | -$60.23M | -$61.30M |
| Investing cash flow | $50.23M | -$82.27M | -$148.45M | -$11.09M | -$6.40M |
| Financing cash flow | -$708,000 | $456,000 | $2.69M | $2.31M | $270.80M |
| Depreciation & amortization | $15.84M | $6.46M | $6.28M | $5.41M | $4.88M |
| Stock-based compensation | $20.72M | $19.99M | $16.82M | $15.38M | $15.97M |
Free plan shows the latest 5 periods; Pro shows all 10 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.